SB-742,457

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
SB-742,457
(IUPAC) ime
3-fenilsulfonil-8-(piperazin-1-il)hinolin
Klinički podaci
Identifikatori
CAS broj 607742-69-8
ATC kod nije dodeljen
PubChem[1][2] 11256720
ChEMBL[3] CHEMBL1083390 YesY
Hemijski podaci
Formula C19H19N3O2S 
Mol. masa 353,44 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status Nije kontrolisan
Način primene Oralno

SB-742,457 je selektivni antagonist 5-HT6 receptora sa uticajem na kogniciju, memoriju, i učenje.[4][5][6][7] On je u razvoju za tretman Alchajmerove bolesti i preliminarno je pokazano da je efikasan u kliničkim ispitivanjima faze II.[6][7][8]

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  4. Upton N, Chuang TT, Hunter AJ, Virley DJ (July 2008). "5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease". Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 5 (3): 458–69. PMID 18625457. doi:10.1016/j.nurt.2008.05.008. 
  5. Idris N, Neill J, Grayson B et al. (January 2010). "Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms". Psychopharmacology 208 (1): 23–36. PMID 19851757. doi:10.1007/s00213-009-1702-5. 
  6. 6,0 6,1 Maher-Edwards G, Zvartau-Hind M, Hunter AJ et al. (December 2009). "Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease". Current Alzheimer Research 7 (5): 374–85. PMID 20043816. 
  7. 7,0 7,1 Rossé G, Schaffhauser H (February 2010). "5-HT(6) Receptor Antagonists as Potential Therapeutics for Cognitive Impairment". Current Topics in Medicinal Chemistry 10 (2): 207–21. PMID 20166958. doi:10.2174/156802610790411036. 
  8. "Search of: SB-742457 - List Results - ClinicalTrials.gov". http://clinicaltrials.gov/ct2/results?term=SB-742457. 

Spoljašnje veze[uredi - уреди | uredi izvor]